OBJECTIVE: Connective tissue growth factor (CTGF), also known as CCN2, is a potent chemotactic and extracellular matrix-inducing matricellular protein that has been implicated in progression of inflammatory and fibroproliferative disorders. An emerging role of CTGF/CCN2 is that of a prosclerotic factor implicated in the development of cardiac disease. Our objective was to determine the role of CTGF/CCN2 as a predictor of cardiovascular events in type 2 diabetes in the Veterans Affairs Diabetes Trial (VADT) cohort. RESEARCH DESIGN AND METHODS: Levels of CTGF/CCN2 were measured in 952 VADT patients a median of 1.9 years after entry into the study. Participants were followed for an average of 3.3 years for vascular outcomes. CTGF/CCN2 categories were defined as below the detectable limit (referent, 54.5%), lower half of detectable values (22.8%), and upper half of detectable values (22.7%). Hazard ratios (HRs) for cardiovascular end points in relation to CTGF/CCN2 categories were calculated by Cox proportional hazards models. RESULTS: During follow-up, 4.8% had a myocardial infarction (MI), 6.9% had an MI or cardiovascular death, and 6.9% died. After adjustments by conventional risk factors, individuals in the highest category of CTGF/CCN2 were at higher risk of MI (HR 2.43 [95% CI 1.15, 5.14]), MI or cardiovascular death (HR 2.71 [95% CI 1.44, 5.08]), and all-cause mortality (HR 2.70 [95% CI 1.43, 5.08]) relative to individuals with CTGF below the detectable limit. CONCLUSIONS: Our study indicates that high levels of CTGF/CCN2 predict future MI and cardiovascular death in patients with type 2 diabetes.
OBJECTIVE:Connective tissue growth factor (CTGF), also known as CCN2, is a potent chemotactic and extracellular matrix-inducing matricellular protein that has been implicated in progression of inflammatory and fibroproliferative disorders. An emerging role of CTGF/CCN2 is that of a prosclerotic factor implicated in the development of cardiac disease. Our objective was to determine the role of CTGF/CCN2 as a predictor of cardiovascular events in type 2 diabetes in the Veterans Affairs Diabetes Trial (VADT) cohort. RESEARCH DESIGN AND METHODS: Levels of CTGF/CCN2 were measured in 952 VADT patients a median of 1.9 years after entry into the study. Participants were followed for an average of 3.3 years for vascular outcomes. CTGF/CCN2 categories were defined as below the detectable limit (referent, 54.5%), lower half of detectable values (22.8%), and upper half of detectable values (22.7%). Hazard ratios (HRs) for cardiovascular end points in relation to CTGF/CCN2 categories were calculated by Cox proportional hazards models. RESULTS: During follow-up, 4.8% had a myocardial infarction (MI), 6.9% had an MI or cardiovascular death, and 6.9% died. After adjustments by conventional risk factors, individuals in the highest category of CTGF/CCN2 were at higher risk of MI (HR 2.43 [95% CI 1.15, 5.14]), MI or cardiovascular death (HR 2.71 [95% CI 1.44, 5.08]), and all-cause mortality (HR 2.70 [95% CI 1.43, 5.08]) relative to individuals with CTGF below the detectable limit. CONCLUSIONS: Our study indicates that high levels of CTGF/CCN2 predict future MI and cardiovascular death in patients with type 2 diabetes.
Authors: Amanda J Rickard; James Morgan; Sophocles Chrissobolis; Alyson A Miller; Christopher G Sobey; Morag J Young Journal: Hypertension Date: 2014-02-24 Impact factor: 10.190
Authors: Hesham M El-Shewy; Mimi Sohn; Parker Wilson; Mi Hye Lee; Samar M Hammad; Louis M Luttrell; Ayad A Jaffa Journal: Mol Endocrinol Date: 2012-03-15
Authors: Hiroshi Kinashi; Lucas L Falke; Tri Q Nguyen; Niels Bovenschen; Jan Aten; Andrew Leask; Yasuhiko Ito; Roel Goldschmeding Journal: Kidney Int Date: 2017-05-23 Impact factor: 10.612
Authors: Sunil K Parapuram; Katherine Thompson; Matthew Tsang; James Hutchenreuther; Christian Bekking; Shangxi Liu; Andrew Leask Journal: Matrix Biol Date: 2015-01-30 Impact factor: 11.583
Authors: Maria F Lopes-Virella; Kelly J Hunt; Nathaniel L Baker; Gabriel Virella; Thomas Moritz Journal: Atherosclerosis Date: 2012-08-21 Impact factor: 5.162
Authors: Miran A Jaffa; Mulugeta Gebregziabher; Sara M Garrett; Deirdre K Luttrell; Kenneth E Lipson; Louis M Luttrell; Ayad A Jaffa Journal: J Transl Med Date: 2018-11-06 Impact factor: 5.531